Several other brokerages also recently commented on NOVN. Deutsche Bank set a CHF 94 price target on Novartis and gave the company a neutral rating in a report on Friday, March 20th. Jefferies Financial Group set a CHF 105 price target on Novartis and gave the company a buy rating in a report on Tuesday, February 25th. Barclays set a CHF 70 price target on Novartis and gave the company a sell rating in a report on Tuesday, March 17th. Goldman Sachs Group set a CHF 113 price target on Novartis and gave the company a buy rating in a report on Wednesday, January 29th. Finally, HSBC set a CHF 86 price target on Novartis and gave the company a neutral rating in a report on Tuesday, November 26th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of CHF 94.83.
Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.
Novartis Company Profile
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Featured Story: Correction
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.